{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=2&sponsor=Merck+Sharp+%26+Dohme+LLC",
    "query": {
      "sponsor": "Merck Sharp & Dohme LLC",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=1&sponsor=Merck+Sharp+%26+Dohme+LLC&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-07T08:59:27.299Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01086527",
      "title": "Genotype Stratified Pharmacokinetic Study of Montelukast",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "10 mg tablet of montelukast (Singulair)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nemours Children's Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": "35 Years",
        "sex": "ALL",
        "summary": "7 Years to 35 Years"
      },
      "enrollment_count": 2,
      "start_date": "2010-03",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2025-02-10",
      "last_synced_at": "2026-06-07T08:59:27.299Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01086527"
    },
    {
      "nct_id": "NCT04840394",
      "title": "Clinical Study of BDB018: Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tumor, Solid"
      ],
      "interventions": [
        {
          "name": "BDB018",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eikon Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2021-06-22",
      "completion_date": "2024-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-06-07T08:59:27.299Z",
      "location_count": 3,
      "location_summary": "Sarasota, Florida • Grand Rapids, Michigan • San Antonio, Texas",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04840394"
    },
    {
      "nct_id": "NCT07216703",
      "title": "A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cervical Cancer"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sacituzumab Tirumotecan",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Rescue Medications",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 1023,
      "start_date": "2026-01-19",
      "completion_date": "2031-10-29",
      "has_results": false,
      "last_update_posted_date": "2026-06-01",
      "last_synced_at": "2026-06-07T08:59:27.299Z",
      "location_count": 14,
      "location_summary": "Miami Beach, Florida • West Palm Beach, Florida • Atlanta, Georgia + 11 more",
      "locations": [
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Edina",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07216703"
    },
    {
      "nct_id": "NCT03631407",
      "title": "Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Neoplasms"
      ],
      "interventions": [
        {
          "name": "Vicriviroc",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 41,
      "start_date": "2018-09-24",
      "completion_date": "2021-06-08",
      "has_results": true,
      "last_update_posted_date": "2024-11-21",
      "last_synced_at": "2026-06-07T08:59:27.299Z",
      "location_count": 6,
      "location_summary": "Scottsdale, Arizona • Encinitas, California • Fresno, California + 3 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03631407"
    },
    {
      "nct_id": "NCT00954941",
      "title": "Ondansetron Versus Aprepitant Plus Ondansetron for Emesis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematologic Diseases",
        "Acute Myelogenous Leukemia",
        "Myelodysplastic Syndrome",
        "Chronic Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "Ondansetron",
          "type": "DRUG"
        },
        {
          "name": "Aprepitant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2009-11",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2015-06-25",
      "last_synced_at": "2026-06-07T08:59:27.299Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00954941"
    },
    {
      "nct_id": "NCT04205929",
      "title": "Use of Curcumin to Treat Unfavorable Bleeding Patterns in Contraceptive Implant Users",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Bleeding",
        "Implants",
        "Breakthrough Bleeding"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Curcumin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Oregon Health and Science University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "15 Years to 45 Years · Female only"
      },
      "enrollment_count": 58,
      "start_date": "2020-04-15",
      "completion_date": "2023-08-01",
      "has_results": true,
      "last_update_posted_date": "2024-07-03",
      "last_synced_at": "2026-06-07T08:59:27.299Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04205929"
    },
    {
      "nct_id": "NCT04291001",
      "title": "Ovarian Function With ENG Implant and UPA Use",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Contraception"
      ],
      "interventions": [
        {
          "name": "ENG implant",
          "type": "DEVICE"
        },
        {
          "name": "oral ulipristal acetate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "University of Utah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 35 Years · Female only"
      },
      "enrollment_count": 40,
      "start_date": "2020-09-04",
      "completion_date": "2024-01-12",
      "has_results": true,
      "last_update_posted_date": "2024-07-12",
      "last_synced_at": "2026-06-07T08:59:27.299Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04291001"
    },
    {
      "nct_id": "NCT02742181",
      "title": "Alvimopan as Rescue in Post op Ileus",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Colorectal Surgery",
        "Ileus"
      ],
      "interventions": [
        {
          "name": "Alvimopan",
          "type": "DRUG"
        },
        {
          "name": "Control Group",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Sharon Stein",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2015-12-02",
      "completion_date": "2018-07-01",
      "has_results": true,
      "last_update_posted_date": "2022-11-18",
      "last_synced_at": "2026-06-07T08:59:27.299Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02742181"
    },
    {
      "nct_id": "NCT04777708",
      "title": "BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Advanced Hepatocellular Carcinoma",
        "BCLC Stage B Hepatocellular Carcinoma",
        "BCLC Stage C Hepatocellular Carcinoma",
        "Refractory Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "Nanoplexed Poly I:C BO-112",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Jonsson Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2021-10-13",
      "completion_date": "2023-03-13",
      "has_results": false,
      "last_update_posted_date": "2023-03-24",
      "last_synced_at": "2026-06-07T08:59:27.299Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04777708"
    },
    {
      "nct_id": "NCT00487539",
      "title": "An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Colitis, Ulcerative"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Golimumab 100 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Golimumab 200 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Golimumab 400 mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Golimumab 50 mg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1065,
      "start_date": "2007-08",
      "completion_date": "2010-10",
      "has_results": true,
      "last_update_posted_date": "2014-02-17",
      "last_synced_at": "2026-06-07T08:59:27.299Z",
      "location_count": 58,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Roseville, California + 55 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Roseville",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Golden",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00487539"
    }
  ]
}